Blood
Articles in this Issue
Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events between chimeric antigen receptor (CAR) T-cell therapy products in multiple myeloma (MM): A nationwide analysis
Abstract Introduction: CAR T-cell therapy represents a pivotal treatment for individuals with relapsed or refractory (R/R) MM. Currently, tw...
Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey
Abstract Introduction Red blood cell (RBC) transfusion guidelines for patients with acute leukemia are lacking and transfusion practices are...
Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study
Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is associated with 5-year survival rates ranging from 53% to 70%, highlighting...
HEXIM1 is a critical regulator of cell cycle progression and terminal maturation during steady-state and stress erythropoiesis
Abstract Background: Erythropoiesis, the dynamic process generating approx. 2.5 million erythrocytes per second, necessitates precise transc...
Elevated interleukin-10 at diagnosis and during treatment independently predicts adverse outcomes in angioimmunoblastic T-cell lymphoma
Abstract Introduction Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma (PTCL) with poor survi...
Mechanisms of acute pain involve spinal IL17-TNF-α/IL-6–p38 MAPK activation in sickle cell disease
Abstract Unique to sickle cell disease (SCD) are unpredictable episodes of acute pain leading to hospitalization and reduced survival. These...
Treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia using hypercvad with ponatinib is associated with excellent survival with selective use of blinatumomab and allogeneic hematopoietic cell transplantation
Abstract Introduction: Tyrosine Kinase Inhibitors (TKI) are standard additions to first-line therapy for patients (pts) with Philadelphia ch...
Maternal anti-αIIb antibodies target fetal hematopoietic stem cells disrupting hematopoiesis and causing pregnancy loss in a murine model of fnait
Abstract Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a life-threatening complication of pregnancy (~1 in 1000 live births) in...
Platelet dynamics and clinical outcomes in patients with heparin-induced thrombocytopenia – single center experience
Abstract INTRODUCTION Heparin-induced thrombocytopenia (HIT) is a life-threatening condition that requires immediate diagnosis and treatment...
Trends in thromboembolism-related mortality among patients with hematologic malignancies in the u.S., 1999–2023: A CDC wonder analysis
Abstract Objective: Hematological malignancies lead to thrombosis through multifactorial mechanisms, including cytokine-mediated endothelial...
A new prognostic index (CLIPI) stratifies risk in advanced cutaneous lymphomas: Associations with treatment pathways, quality of life and survival
Abstract Advanced-stage mycosis fungoides (MF) and Sézary Syndrome (SS) are primary cutaneous T-cell lymphomas (CTCL) have a high symptom an...
Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN
Abstract IntroductionMyeloproliferative neoplasms (MPN) are chronic hematological disorders characterized by clonal expansion of the myeloid...
Real-world survival trends in smoldering versus symptomatic multiple myeloma: A SEER analysis, 2012–2020
Abstract Smoldering multiple myeloma (SMM) represents an asymptomatic intermediate phase between monoclonal gammopathy of undetermined signi...
Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma
Abstract Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell ly...
Pharmacokinetics-guided ATG targeted dosing strategy in unmanipulated haploidentical haematopoietic stem cell transplantation: A randomized, multicenter, phase 3 clinical trial
Abstract Purpose:Fixed dosing of 10 mg/kg anti-thymocyte globulin (ATG) has been a standard prophylaxis for graft-versus-host disease (GVHD)...
Reduced plasma thrombin generation potential and increased thrombomodulin resistance in β-thalassemia/hemoglobin e
Abstract Introduction Compound heterozygosity for β-thalassemia/hemoglobin E (β-thal/HbE) is a prevalent hemoglobinopathy in Southeast Asia,...
Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)
Abstract Background and Significance: Previous clinical results showed that the benefit of available BTK inhibitors may be limited to non-ge...
CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients
Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) is widely used as frontline treatment in older or unfit patients...
Diagnostic disparities in sickle cell disease: Rates and implications
Abstract Diagnosing sickle cell disease later in life can be challenging. Research has highlighted the importance of early diagnosis, partic...
Evaluation of red blood cell exchange practices in the management of sickle cell disease across gulf region hospitals
Abstract Introduction Red blood cell exchange (RBCX) has become a keytherapeutic modalityin managingpatients with sickle cell disease (SCD),...
Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study
Abstract Introduction: NPM1-mutated acute myeloid leukemia (NPM1mut) is a common entity, usually associated with a favorable prognosis. The...
Identification of XPO1 interactors and modulation by selinexor in diffuse large B cell lymphoma
Abstract Background Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Relapsed/refractory (R/R)...
Bleeding rates in patients with congenital hemophilia B without inhibitors: A systematic review and meta-analysis
Abstract INTRODUCTION: Hemophilia B is a rare, X-linked disorder caused by F9 gene mutations, leading to deficient or dysfunctional clotting...
Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma
Abstract Introduction: Marginal zone lymphoma (MZL) is the second most common indolent B-cell non-Hodgkin lymphoma (NHL)...
Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.
Abstract Introduction. Chimeric antigen receptor T-cells (CAR T-cells) have improved outcomes for patients (pts) with relapse or refractory...